Candel Therapeutics (CADL) Common Equity (2020 - 2025)

Candel Therapeutics has disclosed Common Equity across 6 years of filings, most recently posting $51.9 million for Q4 2025.

• Common Equity for Q4 2025 came in at $51.9 million, down 21.72% year-over-year; the trailing twelve-month figure through Dec 2025 was $51.9 million (down 21.72% YoY), and the FY2025 annual result was $51.9 million, down 21.72% from the prior year.
• Common Equity came in at $51.9 million for Q4 2025 at Candel Therapeutics, down from $80.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $90.2 million in Q2 2025 to a low of -$43.2 million in Q2 2021.
• The 5-year median for Common Equity is $49.8 million (2022), against an average of $36.5 million.
• Across the five-year window, Common Equity tumbled 249.85% in 2021 and jumped 1148.95% in 2025, its largest moves.
• Candel Therapeutics' Common Equity stood at $64.1 million in 2021, then retreated by 25.61% to $47.7 million in 2022, then plunged by 73.29% to $12.7 million in 2023, then soared by 420.42% to $66.3 million in 2024, then retreated by 21.72% to $51.9 million in 2025.
• The last three Common Equity figures came in at $51.9 million (Q4 2025), $80.1 million (Q3 2025), and $90.2 million (Q2 2025), per Business Quant data.